Cargando…
Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program
Polycythemia vera (PV) is a BCR-ABL1-negative myeloproliferative neoplasm (MPN) characterized by excessive proliferation of erythroid, myeloid, and megakaryocytic components in the bone marrow, mainly due to a Janus kinase 2 gene mutation (JAK2(V617F)). Givinostat, a histone-deacetylase inhibitor th...
Autores principales: | Rambaldi, Alessandro, Iurlo, Alessandra, Vannucchi, Alessandro M., Martino, Bruno, Guarini, Attilio, Ruggeri, Marco, von Bubnoff, Nikolas, De Muro, Marianna, McMullin, Mary Frances, Luciani, Stefania, Martinelli, Vincenzo, Nogai, Axel, Rosti, Vittorio, Ricco, Alessandra, Bettica, Paolo, Manzoni, Sara, Di Tollo, Silvia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7936975/ https://www.ncbi.nlm.nih.gov/pubmed/33677466 http://dx.doi.org/10.1038/s41408-021-00445-z |
Ejemplares similares
-
Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study
por: Rambaldi, Alessandro, et al.
Publicado: (2020) -
An agenda for future research projects in polycythemia vera and essential thrombocythemia
por: Barbui, Tiziano, et al.
Publicado: (2020) -
Polycythemia vera treatment algorithm 2018
por: Tefferi, Ayalew, et al.
Publicado: (2018) -
New Perspectives on Polycythemia Vera: From Diagnosis to Therapy
por: Iurlo, Alessandra, et al.
Publicado: (2020) -
Polycythemia vera: historical oversights, diagnostic details, and therapeutic views
por: Tefferi, Ayalew, et al.
Publicado: (2021)